We are healthier together
By utilising novel approaches and technologies, as well as partnering with highly respected organisations and academic institutions, we markedly improve the lives of patients, whilst never losing sight of the needs of our employees, partners, investors and other stakeholders.
Our focus is on developing products that can make a positive impact on patient’s lives.
Danilo Casadei Massari | CEO
Research
Have a product innovation that will fit into our portfolio?
Investments
Are you interested in investing in Nemysis?
Research & Development
Iron Hydroxide Adipate Tartrate (IHAT) is our novel and proprietary nanoparticulate chemical entity, designed to safely release bioavailable iron for the remediation of iron level in iron deficiency and iron deficiency Anamia.
IHAT is the first ever EFSA-assessed and EU-authorised nano-iron for human use to supplement iron in case of increased physiological demand.
Other dated iron supplementation products are known to cause adverse gastrointestinal (GI) tract side effects, clearly perceived by the patient and reducing compliance. IHAT is a unique organic acid-doped ferritin nanoparticle that mimics dietary iron and follows its physiological mechanism of absorption by the body, to safely and effectively treat iron deficiency with or without anaemia, whilst minimising the adverse GI side effects commonly associated with other iron supplements.
Endoprotease 40 (E40) is our late-stage development, fast-acting glutenase designed to aid the complete digestion of whole gliadins in gluten, as an adjunct to a Gluten-Free Diet (GFD), safely and effectively limiting the generation of Gluten Immunogenic Peptides (GIPs) that can make the lives of patients with Celiac Disease (CeD) and Non-Celiac Gluten Sensitivity (NCGS) uncomfortable and painful.
Gluten avoidance, including through a GFD, is currently the only available effective therapeutic approach to prevent the generation of GIPs and the resulting symptomatic gluten exposure in CeD and NCGS.
However, individuals who are gluten intolerant or sensitive are often involuntarily at risk of gluten exposure, even when following a GFD.
Taken shortly before a meal, E40 will support the gluten-degrading capability of the physiological enzymatic digestive machinery, minimising the risk of GIP generation and the resulting adverse impact on the small intestinal mucosa.
EDA is our early stage pioneering delivery matrix designed to provide gastro-protection to enzymes and other compounds otherwise sensitive to the gastric environment, enabling their safe delivery in functional form beyond the stomach to the site of action or absorption in the intestine.
A key to nutritional supplementation and contrasting disease progression is preserving a healthy, balanced microbiome.
Maria Cristina Comelli | Director R&D
Stay up to date with our latest news and developments
